Inaugural Summit Will Examine Commercialization, Investment and Partnership Strategies Needed to Succeed in Evolving Biosimilar Landscape
Infocast's Biosimilars World 2016, set to take place March 30 - April 1 in Philadelphia, PA, invites stakeholders from across the biosimilar landscape to explore commercialization and partnering strategies for gaining access to new and emerging markets, examine the current regulatory and legal landscape, and evaluate business models and investment opportunities to accelerate biosimilar growth both in and outside of the U.S.
Following the landmark FDA approval of Sandoz' Zarxio, a number of biologic drugs are coming off patent in the near-term, opening the door for unprecedented opportunities in the biosimilars space. Biotech and pharmaceutical companies face a long road ahead, as biosimilars slowly begin to trickle into the U.S. market. Amidst the current reshaping of the competitive landscape, is great potential for revenue, but only for those companies who are able to successfully develop and market these game-changing drugs. However, the lower price of biosimilars alone does not guarantee commercial success.
Biosimilars World 2016 brings together key industry players from all ends of the biosimilar value chain to discuss obstacles facing widespread commercialization, address complex regulatory challenges, as well as scientific and operational issues. Attendees will hear payer and PBM perspectives on the challenges facing market uptake, explore emerging investment trends, hear the latest updates on FDA approval pathways, and develop viable partnerships with key stakeholders to accelerate biosimilar commercialization.
For more information, to register, or to join as a sponsor visit: biosimilars-world.com.